CD19 and B-cell chronic lymphocytic leukemia: As shown in Figure 1C and 1E, the purified CD19+ CLL cells with 17p deletion were relatively resistant to F-ara-A and Oxaliplatin (60% and 55% survival, respectively), but remained highly sensitive to PEITC (9% survival).